ONCT Oncternal Therapeutics
- 0.5266
- 0.00000.00%
Oncternal Therapeutics News
Oncternal Therapeutics Analyst Ratings
Brookline Capital Maintains Oncternal Therapeutics(ONCT.US) With Hold Rating
Oncternal Therapeutics Price Target Cut to $18.00/Share From $19.00 by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18
Oncternal Therapeutics Analyst Ratings
Oncternal Therapeutics' Positive Clinical Progress and Future Catalysts Underpin Buy Rating
Analysts Offer Insights on Healthcare Companies: Springworks Therapeutics (SWTX), Cyclo Therapeutics (CYTH) and Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Joint (JYNT), Xtant Medical Holdings (XTNT) and Oncternal Therapeutics (ONCT)
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Analyst Ratings
Brookline Capital Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target
Oncternal Therapeutics Analyst Ratings
Buy Rating for Oncternal Therapeutics: Promising Clinical Programs and Potential Catalysts
No Data